|28.06||+0.22 / +0.79%|
Data as of 3:59pm ET
|28.06||0.00 / 0.00%|
The 5 analysts offering 12-month price forecasts for Alnylam Pharmaceuticals Inc have a median target of 28.00, with a high estimate of 36.00 and a low estimate of 27.50. The median estimate represents a -0.21% decrease from the last price of 28.06.
The current consensus among 9 polled investment analysts is to Buy stock in Alnylam Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.